Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2015-11-24 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VILLEFRANCHE-DE-ROUERGUE (12200), Aveyron
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE PERTUISOT : revenue, balance sheet and financial ratios
SELAS PHARMACIE PERTUISOT is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VILLEFRANCHE-DE-ROUERGUE (12200),
this company of category PME
shows in 2025 a net income positive of 152 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE PERTUISOT (SIREN 815180161)
Indicator
2025
2024
2022
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
Net income
151 584 €
237 664 €
328 922 €
207 968 €
148 403 €
61 200 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELAS PHARMACIE PERTUISOT generates positive net income of 152 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 61 k€ -> 152 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
151 584 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 24%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
23.856%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
68.227%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2022
2024
2025
Debt ratio
1057.017
491.804
237.617
61.11
28.716
23.856
Financial autonomy
7.134
13.581
24.34
55.552
66.138
68.227
Repayment capacity
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
23.862025
2022
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good-11 pts over 3 years
In 2025, the debt ratio of SELAS PHARMACIE PERTUISOT (23.86) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
68.23%2025
2022
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good+9 pts over 3 years
In 2025, the financial autonomy of SELAS PHARMACIE PERTUISOT (68.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 323.63. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2022
2024
2025
Liquidity ratio
169.85
178.762
194.103
400.742
318.906
323.629
Interest coverage
None
None
None
None
None
None
Sector positioning
Liquidity ratio
323.632025
2022
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of SELAS PHARMACIE PERTUISOT (323.63) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of SELAS PHARMACIE PERTUISOT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELAS PHARMACIE PERTUISOT is estimated at
2 407 929 €
(range 1 634 032€ - 3 778 373€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1634k€2407k€3778k€
2 407 929 €Range: 1 634 032€ - 3 778 373€
NAF 5 année 2025
Valuation method used
Net Income Multiple
151 584 €
×
15.9x
=2 407 930 €
Range: 1 634 033€ - 3 778 374€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE PERTUISOT with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE PERTUISOT
What is the revenue of SELAS PHARMACIE PERTUISOT ?
The revenue of SELAS PHARMACIE PERTUISOT is not publicly disclosed (confidential accounts filed with INPI).
Is SELAS PHARMACIE PERTUISOT profitable?
Yes, SELAS PHARMACIE PERTUISOT generated a net profit of 152 k€ in 2025.
Where is the headquarters of SELAS PHARMACIE PERTUISOT ?
The headquarters of SELAS PHARMACIE PERTUISOT is located in VILLEFRANCHE-DE-ROUERGUE (12200), in the department Aveyron.
Where to find the tax return of SELAS PHARMACIE PERTUISOT ?
The tax return of SELAS PHARMACIE PERTUISOT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE PERTUISOT operate?
SELAS PHARMACIE PERTUISOT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart